Table 4

Refinement of the DRI

DiseaseStageNo. of patientsHR*Original DRIPercentage of patientsNew DRI Group2-y OS (%)95% CI
Hodgkin lymphoma CR  126 0.36 Int 14 Low 66 63-68 
CLL CR  81 0.47 Low Low 
Mantle cell lymphoma CR  160 0.51 Int Low 
Indolent NHL CR  183 0.53 Low Low 
AML favorable cytogenetics CR  190 0.64 Low Low 
Indolent NHL PR  276 0.71 Low Low 
CLL PR  400 0.78 Low Low 
CML chronic phase 1/2  390 0.82 Low Low 
CML advanced phase  69 0.92 Int 63 Int 51 50-52 
Mantle cell lymphoma PR  149 0.95 Int Int 
Myeloproliferative neoplasm Any 426 0.98 Int Int 
AML intermediate cytogenetics CR  3611 Ref Int Int 
ALL CR1  1023 1.00 Int Int 
T-cell NHL CR  171 1.00 Int Int 
Multiple myeloma CR/VGPR/PR  339 1.03 Int Int 
Aggressive NHL CR  181 1.05 Int Int 
Low-risk MDS adverse cytogenetics Early† 103 1.06 High Int 
T-cell NHL PR  164 1.06 Int Int 
Low-risk MDS intermediate cytogenetics Early† 516 1.09 Int Int 
HL PR  225 1.09 Int Int 
Low-risk MDS intermediate cytogenetics Advanced† 235 1.18 Int Int 
Indolent NHL Advanced† 128 1.21 Int Int 
CLL Advanced 265 1.22 Int Int 
High-risk MDS intermediate cytogenetics Early 364 1.24 Int Int 
Aggressive NHL PR  205 1.26 Int Int 
T-cell NHL Advanced† 93 1.41 High 20 High 33 31-35 
AML favorable cytogenetics Advanced† 34 1.42 Int High 
HL Advanced† 85 1.48 High High 
High-risk MDS intermediate cytogenetics Advanced† 179 1.56 Int High 
High-risk MDS adverse cytogenetics Early 80 1.58 High High 
ALL CR2  407 1.58 Int High 
AML adverse cytogenetics CR  175 1.59 High High 
Mantle cell lymphoma Advanced† 46 1.59 High High 
High-risk MDS adverse cytogenetics Advanced† 30 1.59 Very high High 
BL‡ CR  23 1.65 NA High 
Multiple myeloma Advanced† 150 1.65 High High 
ALL CR3  61 1.70 Int High 
Low-risk MDS adverse cytogenetics Advanced† 32 1.86 Very high High 
AML intermediate cytogenetics Advanced 1227 1.89 High High 
CML blast phase  52 2.02 Int 4 Very high 23 20-27 
ALL Advanced† 235 2.23 High Very high 
Aggressive NHL Advanced† 154 2.54 High Very high 
AML adverse cytogenetics Advanced † 76 2.83 Very high Very high 
BL‡ PR Advanced † 12 5.21 NA Very high 
DiseaseStageNo. of patientsHR*Original DRIPercentage of patientsNew DRI Group2-y OS (%)95% CI
Hodgkin lymphoma CR  126 0.36 Int 14 Low 66 63-68 
CLL CR  81 0.47 Low Low 
Mantle cell lymphoma CR  160 0.51 Int Low 
Indolent NHL CR  183 0.53 Low Low 
AML favorable cytogenetics CR  190 0.64 Low Low 
Indolent NHL PR  276 0.71 Low Low 
CLL PR  400 0.78 Low Low 
CML chronic phase 1/2  390 0.82 Low Low 
CML advanced phase  69 0.92 Int 63 Int 51 50-52 
Mantle cell lymphoma PR  149 0.95 Int Int 
Myeloproliferative neoplasm Any 426 0.98 Int Int 
AML intermediate cytogenetics CR  3611 Ref Int Int 
ALL CR1  1023 1.00 Int Int 
T-cell NHL CR  171 1.00 Int Int 
Multiple myeloma CR/VGPR/PR  339 1.03 Int Int 
Aggressive NHL CR  181 1.05 Int Int 
Low-risk MDS adverse cytogenetics Early† 103 1.06 High Int 
T-cell NHL PR  164 1.06 Int Int 
Low-risk MDS intermediate cytogenetics Early† 516 1.09 Int Int 
HL PR  225 1.09 Int Int 
Low-risk MDS intermediate cytogenetics Advanced† 235 1.18 Int Int 
Indolent NHL Advanced† 128 1.21 Int Int 
CLL Advanced 265 1.22 Int Int 
High-risk MDS intermediate cytogenetics Early 364 1.24 Int Int 
Aggressive NHL PR  205 1.26 Int Int 
T-cell NHL Advanced† 93 1.41 High 20 High 33 31-35 
AML favorable cytogenetics Advanced† 34 1.42 Int High 
HL Advanced† 85 1.48 High High 
High-risk MDS intermediate cytogenetics Advanced† 179 1.56 Int High 
High-risk MDS adverse cytogenetics Early 80 1.58 High High 
ALL CR2  407 1.58 Int High 
AML adverse cytogenetics CR  175 1.59 High High 
Mantle cell lymphoma Advanced† 46 1.59 High High 
High-risk MDS adverse cytogenetics Advanced† 30 1.59 Very high High 
BL‡ CR  23 1.65 NA High 
Multiple myeloma Advanced† 150 1.65 High High 
ALL CR3  61 1.70 Int High 
Low-risk MDS adverse cytogenetics Advanced† 32 1.86 Very high High 
AML intermediate cytogenetics Advanced 1227 1.89 High High 
CML blast phase  52 2.02 Int 4 Very high 23 20-27 
ALL Advanced† 235 2.23 High Very high 
Aggressive NHL Advanced† 154 2.54 High Very high 
AML adverse cytogenetics Advanced † 76 2.83 Very high Very high 
BL‡ PR Advanced † 12 5.21 NA Very high 

Int, intermediate.

*

Hazard ratio for mortality compared with AML intermediate cytogenetics in CR1.

†

Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL, and CLL.

‡

Those categories were not included in the original DRI.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal